1. Home
  2. GKOS vs BILL Comparison

GKOS vs BILL Comparison

Compare GKOS & BILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • BILL
  • Stock Information
  • Founded
  • GKOS 1998
  • BILL 2006
  • Country
  • GKOS United States
  • BILL United States
  • Employees
  • GKOS N/A
  • BILL N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • BILL EDP Services
  • Sector
  • GKOS Health Care
  • BILL Technology
  • Exchange
  • GKOS Nasdaq
  • BILL Nasdaq
  • Market Cap
  • GKOS 5.1B
  • BILL 4.3B
  • IPO Year
  • GKOS 2015
  • BILL 2019
  • Fundamental
  • Price
  • GKOS $94.31
  • BILL $43.71
  • Analyst Decision
  • GKOS Strong Buy
  • BILL Buy
  • Analyst Count
  • GKOS 13
  • BILL 20
  • Target Price
  • GKOS $135.15
  • BILL $64.06
  • AVG Volume (30 Days)
  • GKOS 914.5K
  • BILL 2.3M
  • Earning Date
  • GKOS 04-30-2025
  • BILL 05-08-2025
  • Dividend Yield
  • GKOS N/A
  • BILL N/A
  • EPS Growth
  • GKOS N/A
  • BILL N/A
  • EPS
  • GKOS N/A
  • BILL N/A
  • Revenue
  • GKOS $404,523,000.00
  • BILL $1,422,885,000.00
  • Revenue This Year
  • GKOS $27.89
  • BILL $15.10
  • Revenue Next Year
  • GKOS $27.57
  • BILL $12.93
  • P/E Ratio
  • GKOS N/A
  • BILL $116.99
  • Revenue Growth
  • GKOS 23.92
  • BILL 14.52
  • 52 Week Low
  • GKOS $77.10
  • BILL $36.55
  • 52 Week High
  • GKOS $163.71
  • BILL $100.19
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 50.08
  • BILL 43.49
  • Support Level
  • GKOS $93.52
  • BILL $42.81
  • Resistance Level
  • GKOS $101.57
  • BILL $45.71
  • Average True Range (ATR)
  • GKOS 3.33
  • BILL 1.60
  • MACD
  • GKOS 0.40
  • BILL -0.29
  • Stochastic Oscillator
  • GKOS 42.24
  • BILL 22.10

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Share on Social Networks: